Coherus Prices $50.1M Public Offering; Shares Drop After Filing

Coherus Pharmaceuticals (NASDAQ:CHRS) priced its $50.1 million underwritten public offering at $11.50 per share on February 13, 2026. The offering includes 4.5 million shares of common stock and 150,000 shares of warrants, with簿记-roads managed by Leerink Partners and SVB Leerink. Following the filing, the company's stock closed at $10.25, down 12.1%, on continued weakness in the biopharma sector and broader market volatility.